Imuran Powder for Solution for Injection or Infusion 50mg *

  • Company:

    Aspen
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 10 September 2021

File name

Azat_Inj_IE_S_50mg_v8_1631266217.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 10 September 2021

File name

Azat_Inj_IE_P_50mg_v7_1631265896.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 24 December 2019

File name

Azat_Inj_IE_S_50mg_v7_1577184058.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 24 December 2019

File name

Azat_Inj_IE_P_50mg_v6_1577181066.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 06 December 2019

File name

Azat_Tab_IE_S_50mg_v7_1575632138.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 18 December 2018

File name

Azat_Inj_IE_P_50mg_v5_1545129307.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 18 December 2018

File name

Azat_Inj_IE_S_50mg_v5_1545130213.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 11 October 2017

File name

PIL_9858_666.pdf

Reasons for updating

  • New PIL for new product

Updated on 11 October 2017

Reasons for updating

  • Change to section 6 - date of revision
  • Change to section 2 - what you need to know - warnings and precautions

Updated on 03 May 2017

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 10 January 2017

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 07 April 2014

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 06 March 2013

Reasons for updating

  • Change to improve clarity and readability
  • Change due to user-testing of patient information

Updated on 24 October 2012

Reasons for updating

  • Correction of spelling/typing errors

Updated on 01 June 2011

Reasons for updating

  • Change to MA holder contact details

Updated on 03 May 2011

Reasons for updating

  • Change to marketing authorisation holder

Updated on 12 March 2010

Reasons for updating

  • Change to marketing authorisation holder

Updated on 31 January 2007

Reasons for updating

  • Change to side-effects

Updated on 04 August 2005

Reasons for updating

  • Improved electronic presentation

Updated on 25 May 2005

Reasons for updating

  • New PIL for medicines.ie